异基因造血干细胞移植治疗复发难治性外周T细胞淋巴瘤的临床研究

Clinical Study of Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Peripheral T-Cell Lymphoma

目的:探讨异基因造血干细胞移植(allo-HSCT)治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性。方法:回顾分析2014年9月至2018年9月在航天中心医院血液科接受allo-HSCT治疗的6例复发/难治性外周T细胞淋巴瘤患者的临床资料,观察患者移植并发症和无病生存等情况。结果:6例患者均能耐受预处理方案,均获造血重建,随访至2018年12月,中位随访11.5(1-51)个月,2例发生急性GVHD,5例发生慢性GVHD。6例中死亡1例(病毒性肺炎),其余5例患者无病生存,最长无病生存时间已达51个月。结论:allo-HSCT治疗复发/难治性外周T细胞淋巴瘤安全有效,对于原发耐药患者可作为挽救性治疗技术,预处理方案的优化可能会使allo-HSCT取得更佳的疗效。

Objective:To explore the efficacy and safety of allogeneic hematopoietic stem cell transplantation(alloHSCT)in the treatment of relapsed or refractory peripheral T-cell lymphoma(PTCL).Methods:The clinical data of 6 patients with relapsed or refractory PTCL undergoing allo-HSCT from Sep.2014 to Sep.2018 in the department of hematology,aerospace center hospital were retrospectively analyzed.Complications and disease-free survival after HSCT were observed.Results:All the patients could well tolerate the conditioning regimen and acquired hematopoietic reconstruction.Following up till December 2018,with a median time of 11.5 months(1-51);acute GVHD developed in 2 cases and chronic GVHD developed in 5 cases,Among 6 cases one case died of viral pheumonia and the other 5 patients remained disease-free survival.The longest disease-free survival time has reached 51 months.Conclusion:allo-HSCT is a safe and effective method for relapsed or refractory peripheral T-eell lymphoma,which can be chosen as salvage treatment method for patients with primary resistance.Optimization of the conditioning regimen may result in better efficacy of allo-HSCT.